Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression

• Published in: Molecular cancer research Vol. 14; no. 11; pp. 1159 - 1169
• Main Authors: Mao, Lulu, Summers, Whitney, Xiang, Shulin, Yuan, Lin, Dauchy, Robert T, Reynolds, Amberly, Wren-Dail, Melissa A, Pointer, David, Frasch, Tripp, Blask, David E, Hill, Steven M
• Format: Journal Article
• Language: English
• Published: United States 01.11.2016
• Subjects: Animals; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Cell Line, Tumor; Epithelial-Mesenchymal Transition - drug effects; Female; Gene Expression Regulation, Neoplastic - drug effects; Humans; MCF-7 Cells; Melatonin - administration & dosage; Melatonin - pharmacology; Mice; Neoplasm Metastasis; Phosphorylation; Receptor, ErbB-2 - genetics; Ribosomal Protein S6 Kinases, 90-kDa - metabolism; Signal Transduction; Xenograft Model Antitumor Assays
• ISSN: 1541-7786; 1557-3125
• DOI: 10.1158/1541-7786.MCR-16-0158

The importance of the circadian/melatonin signal in suppressing the metastatic progression of breast and other cancers has been reported by numerous laboratories including our own. Currently, the mechanisms underlying the antimetastatic actions of melatonin have not been well established. In the present study, the antimetastatic actions of melatonin were evaluated and compared on the ERα-negative, Her2-positive SKBR-3 breast tumor cell line and ERα-positive MCF-7 cells overexpressing a constitutively active HER2.1 construct (MCF-7Her2.1 cells). Activation of Her2 is reported to induce the expression and/or phosphorylation-dependent activation of numerous kinases and transcription factors that drive drug resistance and metastasis in breast cancer. A key signaling node activated by the Her2/Mapk/Erk pathway is Rsk2, which has been shown to induce numerous signaling pathways associated with the development of epithelial-to-mesenchymal transition (EMT) and metastasis including: Creb, Stat3, cSrc, Fak, Pax, Fascin, and actin polymerization. The data demonstrate that melatonin (both endogenous and exogenous) significantly represses this invasive/metastatic phenotype through a mechanism that involves the suppression of EMT, either by promoting mesenchymal-to-epithelial transition, and/or by inhibiting key signaling pathways involved in later stages of metastasis. These data, combined with our earlier in vitro studies, support the concept that maintenance of elevated and extended duration of nocturnal melatonin levels plays a critical role in repressing the metastatic progression of breast cancer. Melatonin inhibition of Rsk2 represses the metastatic phenotype in breast cancer cells suppressing EMT or inhibiting other mechanisms that promote metastasis; disruption of the melatonin signal may promote metastatic progression in breast cancer. Mol Cancer Res; 14(11); 1159-69. ©2016 AACR.